TECX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

8 Analyst Rating

Wall Street analysts forecast TECX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECX is 85.00 USD with a low forecast of 76.00 USD and a high forecast of 101.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

76.00

Averages

85.00

High

101.00

Current: 0.000

Low

76.00

Averages

85.00

High

101.00

Truist

Danielle Brill

Buy

downgrade

$64 -> $60

2026-01-08

New

Reason

Truist

Danielle Brill

Price Target

$64 -> $60

2026-01-08

New

downgrade

Buy

Reason

Truist analyst Danielle Brill lowered the firm's price target on Tectonic Therapeutic to $60 from $64 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.

Oppenheimer

Outperform

initiated

$80

2025-09-03

Reason

Oppenheimer

Price Target

$80

2025-09-03

initiated

Outperform

Reason

Oppenheimer initiated coverage of Tectonic Therapeutic with an Outperform rating and $80 price target. The firm likes the prospects of the company's lead asset TX45 to address prevalent and progressive cardiovascular disorders that are inadequately treated. The analyst is optimistic ahead of next year's Phase 2 readout in pulmonary hypertension with heart failure with preserved ejection fraction, which it believes could pave the way to multi-billion global sales opportunity.

Truist

initiated

$64

2025-07-21

Reason

Truist

Price Target

$64

2025-07-21

initiated

Reason

Truist initiated coverage of Tectonic Therapeutic with a Buy rating and $64 price target. Tectonic is advancing lead relaxin asset, TX45 for Group 2 pulmonary hypertension-heart failure with preserved ejection fraction and Truist is cautiously optimistic that TX45 will be successful in its ongoing Phase 2 study, the analyst tells investors in a research note. Truist likes the current risk-reward.

Raymond James

Outperform

initiated

$76

2025-06-10

Reason

Raymond James

Price Target

$76

2025-06-10

initiated

Outperform

Reason

Raymond James resumed coverage of Tectonic Therapeutic with an Outperform rating and $76 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS - probability of success - lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the company, the firm contends that its lead asset, TX45 offers among the most compelling risk/reward propositions within a biotech landscape currently awash with suppressed valuations and favorable skew, Raymond James added. The firm notes that the ongoing Phase 2 targets a high unmet need indication which favorably aligns with relaxin's multi-modal mechanism of action.

LifeSci Capital

Outperform

initiated

$87

2025-06-05

Reason

LifeSci Capital

Price Target

$87

2025-06-05

initiated

Outperform

Reason

LifeSci Capital initiated coverage of Tectonic Therapeutic with an Outperform rating and $87 price target.

Mizuho

Uy Ear

Outperform

maintain

$51 -> $85

2025-05-15

Reason

Mizuho

Uy Ear

Price Target

$51 -> $85

2025-05-15

maintain

Outperform

Reason

Mizuho analyst Uy Ear raised the firm's price target on Tectonic Therapeutic to $85 from $51 and keeps an Outperform rating on the shares. The firm believes the blockbuster potential of TX45 in pulmonary hypertension remains underappreciated at current shared levels as investors continue to be concerned about the potential effectiveness of the relaxin class given Lilly's futility finding in the Phase 2 trial of volenrelaxin in heart failure. Mizuho said it recently discovered the protocol for the Phase 2 trial of AZD3427 in group 2 pulmonary hypertension "that should reverse this sentiment." The protocol calls for AstraZeneca to conduct an interim analysis, and based on AZD3427's Phase 2 trial timeline, AstraZeneca conducted this interim analysis and found no futility as AZD3427's Phase 2 trials remain ongoing, contends the firm. It We increased its probability of success for TX45 from 35% to 55%.

Valuation Metrics

The current forward P/E ratio for Tectonic Therapeutic Inc (TECX.O) is -4.19, compared to its 5-year average forward P/E of -5.47. For a more detailed relative valuation and DCF analysis to assess Tectonic Therapeutic Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.47

Current PE

-4.19

Overvalued PE

-3.42

Undervalued PE

-7.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.42

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.38

Undervalued EV/EBITDA

-1.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 215.5% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TECX News & Events

Events Timeline

No data

News

9.0

2025-10-30NASDAQ.COM

TECX, GKOS, GH, ALGN, NMRA Experience After-Hours Surge Following Clinical Data and Earnings Reports

4.0

2025-09-05TipRanks

Three Biotech Stocks Rated 'Strong Buy' by Analysts with Potential Upside Exceeding 300%

4.0

2025-09-03Benzinga

Oppenheimer Begins Coverage of Tectonic Therapeutics with Outperform Rating and Sets Price Target at $80

People Also Watch

Frequently Asked Questions

What is Tectonic Therapeutic Inc (TECX) stock price today?

The current price of TECX is 20.835 USD — it has decreased -2.91 % in the last trading day.

What is Tectonic Therapeutic Inc (TECX)'s business?

Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).

What is the price predicton of TECX Stock?

What is Tectonic Therapeutic Inc (TECX)'s revenue for the last quarter?

Tectonic Therapeutic Inc revenue for the last quarter amounts to -21.89M USD, increased 11.47 % YoY.

What is Tectonic Therapeutic Inc (TECX)'s earnings per share (EPS) for the last quarter?

Tectonic Therapeutic Inc. EPS for the last quarter amounts to -17996000.00 USD, decreased -8.91 % YoY.

What changes have occurred in the market's expectations for Tectonic Therapeutic Inc (TECX)'s fundamentals?

The market is revising No Change the revenue expectations for Tectonic Therapeutic, Inc. (TECX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 21.98%.

How many employees does Tectonic Therapeutic Inc (TECX). have?

Tectonic Therapeutic Inc (TECX) has 51 emplpoyees as of January 09 2026.

What is Tectonic Therapeutic Inc (TECX) market cap?

Today TECX has the market capitalization of 401.65M USD.